Newsroom

Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, today jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio’s Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. Scopio’s X100 / X100HT with FF-BMA Application are CE-Marked.

Biogen Inc. (Nasdaq: BIIB), Beckman Coulter, Inc. and Fujirebio announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialize new tests for tau pathology in Alzheimer’s disease (AD). The development of tau-specific blood-based biomarkers that can measure a patient’s tau burden could provide critical insights into the underlying pathological processes of AD and may help advance the development of a new generation of therapies impacting tau pathology.